Moreover, preclinical studies have demonstrated that neutralization of the CD47–SIRPα axis lowered the threshold for macrophage activation, enhancing the efficacy of various therapeutic antibodies such as rituximab in non-Hodgkin lymphoma, the anti-HER2 antibody in breast cancer, the anti-CD271 antibody in melanoma, and the anti-CD56 antibody in small-cell lung cancer [130]. Here, ERBB2 is linked to breast cancer.